Japan Eyes Cutting Reimbursement For COVID-19 Drugs
Large Reduction For Xocova?
Japan will end full reimbursement coverage for COVID-19 therapeutic drugs from October, after downgrading the status of the virus to the same level as seasonal flu in early May. As authorities discuss the possible coverage reduction, a larger than usual price cut may also be applied to Shionogi's oral COVID antiviral Xocova.
You may also be interested in...
Japanese regulatory authorities have announced a set of additional reimbursement price cuts for selected products in August, under which Novartis’s heart failure drug Entresto will see its price slashed by 15%. A batch of other newly approved drugs has also been priced.
Amid positive ongoing forex impact, Astellas, Shionogi and Daiichi Sankyo logged solid fiscal years and Chugai has good growth in its first quarter, although some of the majors are expecting a decline in sales as demand due to COVID-19 wanes. Even so, Shionogi logged record results on the back on government procurement of its pandemic antiviral.
A new digital health venture set up by Eisai plans to start operations in Japan from April 2024 with services related to cognitive impairment and dementia, in line with the Japanese firm's therapeutic advances in this area.